Evaluation of a BK virus viral load assay using the QIAGEN Artus BK Virus RG PCR test

2012 ◽  
Vol 54 (3) ◽  
pp. 260-264 ◽  
Author(s):  
Hanna Rennert ◽  
Stephen G. Jenkins ◽  
Carmen Azurin ◽  
John Sipley
2018 ◽  
Vol 90 (4) ◽  
pp. 257-263 ◽  
Author(s):  
Hanna Rennert ◽  
Girish Ramrattan ◽  
Zhengming Chen ◽  
Patrick McIntire ◽  
Alber Michaeel ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 297
Author(s):  
Fabbio Marcuccilli ◽  
Stephane Chevaliez ◽  
Thomas Muller ◽  
Luna Colagrossi ◽  
Giulia Abbondanza ◽  
...  

Accurate measurement of the hepatitis B virus (HBV) DNA is important for the management of patients with chronic HBV infection. Here, the performance of the Xpert® HBV Viral Load test (Xpert HBV Viral Load) versus the Roche COBAS® Ampliprep/COBAS® TaqMan® system (CAP/CTM HBV) HBV test v2.0 was evaluated. From September 2017 to December 2017, a total of 876 prospectively collected or archived serum or EDTA plasma specimens from subjects chronically infected with HBV were tested using the Xpert HBV Viral Load and the CAP/CTM HBV v2.0 assays. Of the 876 specimens tested, 560 were within the quantitative range of both assays. The agreement between the two methods was 90.0%. No difference in plasma or serum samples was observed. Deming regression analysis showed a good correlation of the Xpert HBV Viral Load assay with the CAP/CTM HBV v2.0 assay. The Bland–Altman analysis showed a good agreement between the results of the Xpert HBV Viral Load assay and the CAP/CTM HBV assay, with a mean difference (±1.96 standard deviation) of 0.0091 ± 0.3852 Log IU/mL. Comparing the two assays, only nineteen specimens (2.1%) had a difference greater than 1.96 times the standard deviation. The Xpert® HBV Viral Load test is suitable for monitoring patients with HBV infection and is useful in diagnostic settings.


2011 ◽  
Vol 49 (4) ◽  
pp. 1631-1634 ◽  
Author(s):  
T. P. Young ◽  
G. Cloherty ◽  
S. Fransen ◽  
L. Napolitano ◽  
P. Swanson ◽  
...  

2018 ◽  
Vol 68 ◽  
pp. S167
Author(s):  
F. Lamoury ◽  
S. Bajis ◽  
B. Hajarizadeh ◽  
A. Marshall ◽  
M. Martinello ◽  
...  
Keyword(s):  

2003 ◽  
Vol 75 (1) ◽  
pp. 105-112 ◽  
Author(s):  
Abhay Vats ◽  
Ron Shapiro ◽  
Parmjeet Singh Randhawa ◽  
Velma Scantlebury ◽  
Acar Tuzuner ◽  
...  

Science ◽  
1996 ◽  
Vol 271 (5252) ◽  
pp. 1043-1043
Author(s):  
Barton F. Haynes

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Babbiker Mohammed Taher Gorish ◽  
Mohammed Elfatih Hussein Ournasseir ◽  
Iman Mohammed Shammat

Abstract Background Polyomavirus hominis1, also called BK virus (BKV) is a well-known etiological agent of renal transplant nephropathy and cystitis. Recently, it got great attention from the researcher as a principal predisposing factor for different kinds of cancers including prostate cancer (PCa). Thus, this study aims to determine the correlation between BKV infection and PCa through a descriptive case-control based study. Methods A total of 55 paraffin-embedded tissue blocks of patients with PCa and another 55 tissue blocks from BPH patients were obtained. In parallel, respective urine samples were collected from all the cases and controls. The existence of BKV large T antigen (LTAg) was analyzed by Direct Immunofluorescence assay. Only BKV LTAg positive specimens were further analyzed for the presence of viral DNA by using a conventional PCR then subjected to viral load quantitation by using Q-PCR. Result BKV LTAg was identified in 30% (17/55) of cases tissue specimens and only in 7% (4/55) of the controls tissue specimens with P-value 0.002 and Odd ratio 5.7. The conventional PCR detects the BKV DNA in 16 out of 17 cases specimens while only two out of four controls specimens were identified with a viral DNA. The mean of the BKV DNA load was higher significantly among cases 6733 ± 6745 copies/ml when compared to controls 509.0 ± 792.9 copies/m with a p-value of 0.002. Conclusion More BKV prevalence with high viral load was observed in PCa patients tissue compared to BPH specimens. PCa Gleason scores 9 and 7 were the most cancer grades identified with the presence of BKV DNA. Our findings are thus consistent with a significant link between the BKV infection and the PCa risk. Prostate or seminal fluids should be selected as principal specimens for future studies and can, therefore, be designated as screening samples to find early virus evidence in the prostate tissue. Detection of early virus evidence may help to reduce the risk of PCa cancer due to BKV.


2020 ◽  
Vol 75 (12) ◽  
pp. 3510-3516 ◽  
Author(s):  
Jessica M Fogel ◽  
David Bonsall ◽  
Vanessa Cummings ◽  
Rory Bowden ◽  
Tanya Golubchik ◽  
...  

Abstract Objectives To evaluate the performance of a high-throughput research assay for HIV drug resistance testing based on whole genome next-generation sequencing (NGS) that also quantifies HIV viral load. Methods Plasma samples (n = 145) were obtained from HIV-positive MSM (HPTN 078). Samples were analysed using clinical assays (the ViroSeq HIV-1 Genotyping System and the Abbott RealTime HIV-1 Viral Load assay) and a research assay based on whole-genome NGS (veSEQ-HIV). Results HIV protease and reverse transcriptase sequences (n = 142) and integrase sequences (n = 138) were obtained using ViroSeq. Sequences from all three regions were obtained for 100 (70.4%) of the 142 samples using veSEQ-HIV; results were obtained more frequently for samples with higher viral loads (93.5% for 93 samples with >5000 copies/mL; 50.0% for 26 samples with 1000–5000 copies/mL; 0% for 23 samples with <1000 copies/mL). For samples with results from both methods, drug resistance mutations (DRMs) were detected in 33 samples using ViroSeq and 42 samples using veSEQ-HIV (detection threshold: 5.0%). Overall, 146 major DRMs were detected; 107 were detected by both methods, 37 were detected by veSEQ-HIV only (frequency range: 5.0%–30.6%) and two were detected by ViroSeq only. HIV viral loads estimated by veSEQ-HIV strongly correlated with results from the Abbott RealTime Viral Load assay (R2 = 0.85; n = 142). Conclusions The NGS-based veSEQ-HIV method provided results for most samples with higher viral loads, was accurate for detecting major DRMs, and detected mutations at lower levels compared with a method based on population sequencing. The veSEQ-HIV method also provided HIV viral load data.


PLoS ONE ◽  
2012 ◽  
Vol 7 (8) ◽  
pp. e43882 ◽  
Author(s):  
Chanson J. Brumme ◽  
Luke C. Swenson ◽  
Brian Wynhoven ◽  
Benita Yip ◽  
Stuart Skinner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document